PROTALIX BIOTHERAPEUTICS, INC. (PLX): Protalix BioTherapeutics Announces Prese...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

PROTALIX BIOTHERAPEUTICS, INC. (PLX)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	3
Posts	230
Boards Moderated	0
Alias Born	02/28/2017

Re: None

Monday, 11/20/2017 7:42:31 AM

Monday, November 20, 2017 7:42:31 AM

Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference

Oral Presentation of Long-Term Results from the Phase I/II Open-Label Extension Trial of PRX-102 for Fabry Disease

CARMIEL, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) announced today two-year results from the phase I/II open-label extension clinical trial of pegunigalsidase alfa, or PRX-102, for the treatment of Fabry disease will be presented at the New Horizons in Fabry Disease Conference taking place November 24-25 in Prague, Czech Republic.

The oral presentation titled “Enzyme replacement therapies in development – preclinical and clinical data and experience with pegunigalsidase alfa,” will be given by Prof. Raphael Schiffmann, Director, Institute of Metabolic Disease at the Baylor Research Institute, Dallas, Texas, at a session taking place on Friday, November 24 from 4:00 PM to 6:00 PM CET.

Additional details on the conference can be found at http://www.horizons-fabry.com/.

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent PLX News

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/02/2024 11:36:07 AM
Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 11:56:21 AM
Levicept Appoints Eliot Forster as CEO • GlobeNewswire Inc. • 11/30/2023 09:00:00 AM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 12:50:52 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 12:22:32 PM
Upcoming Earnings Release Paired With Price Target Raise Sends Stock Soaring • AllPennyStocks.com • 10/31/2023 08:40:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/20/2023 10:50:07 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:58 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:54 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:51 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:50 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/15/2023 08:46:57 PM
Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/15/2023 08:45:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2023 10:58:32 AM
Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • PR Newswire (US) • 09/06/2023 10:50:00 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2023 08:30:58 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2023 08:30:42 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2023 08:30:28 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2023 08:30:12 PM
Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/11/2023 08:31:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 11:02:19 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 10:59:00 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 08:41:59 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/07/2023 08:30:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 11:24:42 AM

More PLX News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow